Kezdőlap・Részvénylista・Johnson and Johnson

Johnson and Johnson

Lezárt

SzektorEgészségügy

260.04 0.23

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

258.5

Maximum

261.83

Fő mutatók
By Trading Economics
Bevétel	299M 5.5B
Értékesítés	1.2B 25B
P/E Szektor átlag	29.548 68.51
Egy részvényre jutó nyereség	2.9
Osztalékhozam	2.04
Profit margin	21.865
Munkavállalók	138,200
EBITDA	-1.1B 7.2B

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+7.33% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	2.04% 2.29%
Következő eredményjelentés	2026. okt. 13.
Következő osztalékfizetési dátum	2026. szept. 8.
Következő korábbi osztalék dátum	2026. aug. 25.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-5.5B 613B
Előző nyitás	259.81
Előző zárás	260.04

Hangulat hírek alapján

By Acuity

23%

77%

41 / 340 Rangsor szerint Healthcare

Johnson and Johnson Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 10. 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

2026. aug. 8. 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

2026. aug. 7. 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

2026. aug. 6. 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

2026. aug. 5. 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

2026. aug. 4. 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

2026. aug. 3. 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

2026. aug. 1. 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

2026. júl. 31. 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

2026. júl. 30. 18:22 UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

2026. júl. 29. 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

2026. júl. 28. 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

2026. júl. 27. 23:31 UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

2026. júl. 24. 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

2026. júl. 23. 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

2026. júl. 22. 23:36 UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

2026. júl. 21. 23:11 UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

2026. júl. 20. 19:26 UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Társak összehasonlítása

Árváltozás

Johnson and Johnson Előrejelzés

Célár

By TipRanks

7.33% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 281 USD 7.33%

Magas 305 USD

Alacsony 255 USD

17 Wall Street elemző 12 hónapos célárain alapulva a(z)Johnson and Johnson termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

17 ratings

Vétel

Tartás

Eladás

17 Wall Street elemző célárain alapulva a(z)Johnson and Johnson termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

41 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.